
  
    
      
        Background_NNP
        Regular_JJ use_NN of_IN aspirin_NN and_CC other_JJ non-steroidal_JJ
        anti-inflammatory_JJ dugs_NNS (_( NSAIDs_NNP )_) has_VBZ been_VBN consistently_RB
        associated_VBN with_IN reduced_VBN risk_NN of_IN colorectal_NN cancer_NN and_CC
        adenoma_NN [_NN 1_CD 2_CD 3_CD 4_CD ]_NN ,_, possibly_RB due_JJ to_TO NSAID-related_NNP
        inhibition_NN of_IN prostaglandin_NN synthesis_NN ,_, enhancement_NN of_IN
        cellular_JJ immune_JJ response_NN ,_, or_CC induction_NN of_IN apoptosis_NNS [_NN 5_CD 6_CD 7_CD
        8_CD ]_NN ._. A_DT number_NN of_IN epidemiological_JJ studies_NNS have_VBP investigated_VBN
        the_DT potential_JJ protective_JJ effect_NN of_IN NSAIDs_NNP with_IN respect_NN to_TO
        other_JJ cancer_NN sites_NNS ._. There_EX is_VBZ some_DT evidence_NN that_IN regular_JJ and_CC
        prolonged_JJ NSAID_NNP use_NN is_VBZ associated_VBN with_IN reduced_VBN risk_NN of_IN
        cancers_NNS of_IN the_DT esophagus_JJ [_NN 3_CD 9_CD 10_CD ]_NN stomach_NN [_NN 3_CD 9_CD 11_CD ]_NN ,_,
        ovary_JJ [_NN 12_CD 13_CD ]_NN ,_, and_CC female_JJ breast_NN [_NN 14_CD 15_CD 16_CD ]_NN ._.
        Although_IN there_EX is_VBZ a_DT growing_VBG body_NN of_IN epidemiological_JJ
        evidence_NN on_IN the_DT role_NN of_IN aspirin_NN and_CC other_JJ NSAIDs_NNP in_IN the_DT
        chemoprevention_NN of_IN lung_NN cancer_NN (_( Table_NNP 1_CD ._. ;_: [_NN 14_CD 17_CD 18_CD 19_CD 20_CD
        21_CD 22_CD 23_CD ]_NN )_) ,_, about_IN half_NN of_IN these_DT studies_NNS published_VBN to_TO date_NN
        were_VBD not_RB specifically_RB designed_VBN to_TO investigate_VB this_DT
        association_NN [_NN 17_CD 18_CD 19_CD 21_CD ]_NN ._. In_IN a_DT randomized_JJ trial_NN aimed_VBN
        at_IN examining_VBG the_DT effect_NN of_IN aspirin_NN in_IN the_DT prevention_NN of_IN
        cardiovascular_JJ disease_NN in_IN male_JJ physicians_NNS ,_, Peto_NNP et_CC al_NN [_NN 17_CD
        ]_NN first_RB noted_VBD lower_JJR lung_NN cancer_NN mortality_NN rates_NNS in_IN the_DT
        aspirin_NN intervention_NN group_NN compared_VBN to_TO the_DT placebo_NN group_NN ._.
        Two_CD subsequent_JJ cohort_NN studies_NNS demonstrated_VBD associations_NNS
        with_IN regular_JJ [_NN 18_CD ]_NN or_CC frequent_JJ aspirin_NN use_NN [_NN 19_CD ]_NN among_IN
        women_NNS ,_, but_CC not_RB men_NNS ._. In_IN contrast_NN ,_, in_IN a_DT prospective_JJ analysis_NN
        of_IN the_DT NHANES_NNP I_PRP follow-up_JJ study_NN ,_, Schreinemachers_NNP &_CC
        Everson_NNP [_NN 14_CD ]_NN reported_VBD lower_JJR incidence_NN of_IN lung_NN cancer_NN only_RB
        among_IN men_NNS classified_VBN as_IN recent_JJ aspirin_NN users_NNS ._. Rosenberg_NNP [_NN
        20_CD ]_NN observed_VBD no_DT strong_JJ evidence_NN for_IN a_DT chemopreventive_JJ role_NN
        of_IN aspirin_NN in_IN a_DT hospital-based_JJ case-control_JJ study_NN ;_: whereas_IN
        Langman_NNP et_CC al_NN ._. [_NN 21_CD ]_NN ,_, in_IN a_DT record-based_JJ case-control_JJ
        study_NN ,_, reported_VBD a_DT borderline_NN significant_JJ risk_NN reduction_NN
        associated_VBN with_IN frequent_JJ prescriptions_NNS of_IN NSAIDs_NNP ._. Most_JJS
        recently_RB ,_, results_NNS from_IN a_DT case-control_JJ study_NN ,_, nested_JJ within_IN
        the_DT NYU_NNP Women_NNP 's_POS Health_NNP Study_NNP [_NN 22_CD ]_NN ,_, indicated_VBD that_IN women_NNS
        classified_VBN as_IN regular_JJ aspirin_NN users_NNS were_VBD at_IN a_DT marked_VBN ,_, and_CC
        statistically_RB significant_JJ ,_, reduced_VBN risk_NN of_IN non-small_JJ cell_NN
        lung_NN cancer_NN (_( NSCLC_NNP )_) compared_VBN to_TO women_NNS classified_VBN as_IN
        non-users_JJ ;_: however_RB ,_, no_DT significant_JJ associations_NNS were_VBD
        observed_VBN for_IN all_DT histological_JJ types_NNS combined_VBN ._. Another_DT
        recent_JJ case-control_JJ study_NN investigated_VBD the_DT effect_NN of_IN
        aspirin_NN on_IN lung_NN cancer_NN risk_NN in_IN a_DT sample_NN of_IN heavy_JJ smokers_NNS [_NN
        23_CD ]_NN ._. Results_NNS indicated_VBD that_IN daily_JJ aspirin_NN use_NN was_VBD
        strongly_RB associated_VBN with_IN reduced_VBN risk_NN ;_: this_DT effect_NN was_VBD
        apparent_JJ for_IN both_DT men_NNS and_CC women_NNS ._. We_PRP conducted_VBD a_DT
        hospital-based_JJ case-control_JJ study_NN to_TO further_VB investigate_VB
        the_DT overall_JJ association_NN between_IN aspirin_NN use_NN and_CC lung_NN cancer_NN
        risk_NN ,_, and_CC to_TO add_VB to_TO the_DT limited_JJ body_NN of_IN evidence_NN on_IN the_DT
        potential_JJ effect_NN modifying_VBG roles_NNS of_IN tumor_NN histology_NN and_CC
        cigarette_NN smoking_NN on_IN the_DT chemopreventive_JJ role_NN of_IN aspirin_NN in_IN
        lung_NN tumorigenesis_NNS ._.
      
      
        Methods_NNP
        
          Study_NN population_NN
          The_DT study_NN population_NN included_VBD individuals_NNS who_WP received_VBD
          medical_JJ services_NNS at_IN the_DT Roswell_NNP Park_NNP Cancer_NNP Institute_NNP
          (_( RPCI_NNP )_) between_IN 1982_CD and_CC 1998_CD ,_, and_CC who_WP agreed_VBD to_TO complete_VB
          a_DT comprehensive_JJ epidemiological_JJ questionnaire_NN ._. Informed_NNP
          consent_NN was_VBD obtained_VBN from_IN all_DT participants_NNS ._. The_DT case_NN
          group_NN consisted_VBD of_IN 868_CD individuals_NNS with_IN primary_JJ ,_, incident_NN
          lung_NN cancer_NN ,_, identified_VBN from_IN the_DT RPCI_NNP tumor_NN registry_NN and_CC
          Diagnostic_NNP Index_NNP ._. Controls_NNP included_VBD 935_CD individuals_NNS ,_,
          randomly_RB selected_VBN from_IN a_DT pool_NN of_IN 7957_CD eligible_JJ
          individuals_NNS ,_, who_WP received_VBD medical_JJ services_NNS at_IN RPCI_NNP for_IN
          non-neoplastic_JJ conditions_NNS ._. These_DT participants_NNS came_VBD to_TO
          RPCI_NNP with_IN a_DT suspicion_NN of_IN neoplastic_JJ disease_NN ,_, but_CC were_VBD not_RB
          diagnosed_VBN with_IN either_DT benign_JJ or_CC malignant_JJ conditions_NNS ._. The_DT
          most_RBS frequently_RB utilized_JJ services_NNS among_IN the_DT controls_NNS were_VBD
          carried_VBN out_IN in_IN the_DT breast_NN clinic_NN (_( 13_CD %_NN )_) ,_, dermatology_NN
          clinic_NN (_( 12_CD %_NN )_) ,_, gastrointestinal_NN clinic_NN (_( 15_CD %_NN )_) ,_, and_CC
          sarcoma_NN /_NN melanoma_NN clinic_NN (_( 15_CD %_NN )_) ._. The_DT remaining_VBG controls_NNS
          were_VBD seen_VBN in_IN a_DT variety_NN of_IN clinics_NNS at_IN our_PRP$ institute_NN ,_,
          including_VBG gynecological_JJ oncology_NN ,_, hematology_NN ,_, head_NN and_CC
          neck_NN ,_, radiotherapy_NN ,_, and_CC urology_NN ;_: however_RB the_DT proportion_NN
          of_IN controls_NNS seen_VBN at_IN these_DT clinics_NNS was_VBD less_JJR than_IN five_CD
          percent_NN of_IN all_DT control_NN participants_NNS ._. Controls_NNP were_VBD
          frequency_NN matched_VBN to_TO cases_NNS on_IN sex_NN and_CC five-year_JJ age_NN
          intervals_NNS ._.
        
        
          Questionnaire_NNP
          All_DT participants_NNS completed_VBD the_DT Patient_NNP Epidemiology_NNP
          Data_NNP System_NNP (_( PEDS_NNP )_) questionnaire_NN ,_, which_WDT is_VBZ offered_VBN to_TO all_DT
          new_JJ patients_NNS as_IN part_NN of_IN the_DT admission_NN process_NN ,_, and_CC is_VBZ
          returned_VBN by_IN approximately_RB 50_CD percent_NN of_IN new_JJ patients_NNS ._. The_DT
          16_CD -_: page_NN instrument_NN covers_VBZ information_NN on_IN tobacco_NN and_CC
          alcohol_NN consumption_NN ,_, family_NN history_NN of_IN cancer_NN ,_,
          occupational_NN and_CC environmental_JJ exposures_NNS ,_, reproductive_JJ
          and_CC medical_JJ histories_NNS ,_, and_CC diet_NN ._. The_DT instrument_NN also_RB
          assesses_NNS aspirin_NN use_NN relevant_JJ to_TO the_DT period_NN prior_RB to_TO the_DT
          onset_NN of_IN disease_NN ._. Specifically_RB ,_, the_DT instrument_NN queried_VBN :_:
          '_POS If_IN you_PRP are_VBP currently_RB ill_JJ ,_, indicate_VBP how_WRB often_RB you_PRP took_VBD
          these_DT medications_NNS before_IN the_DT illness_NN '_'' ._. Participants_NNS
          provided_VBD information_NN on_IN how_WRB many_JJ times_NNS a_DT week_NN and_CC for_IN how_WRB
          many_JJ years_NNS they_PRP took_VBD aspirin_NN ._. Participants_NNS who_WP reported_VBD
          aspirin_NN use_NN at_IN least_JJS once_RB a_DT week_NN for_IN one_CD year_NN were_VBD
          classified_VBN as_IN regular_JJ aspirin_NN users_NNS ._. Dosage_NNP of_IN use_NN was_VBD
          assessed_VBN by_IN comparing_VBG participants_NNS who_WP were_VBD classified_VBN as_IN
          non-users_JJ to_TO participants_NNS who_WP reported_VBD that_IN they_PRP had_VBD
          taken_VBN aspirin_NN either_CC one_CD to_TO six_CD times_NNS per_IN week_NN or_CC seven_CD
          or_CC more_JJR times_NNS per_IN week_NN ._. Duration_NNP of_IN use_NN was_VBD evaluated_VBN by_IN
          comparing_VBG non-users_JJ to_TO participants_NNS who_WP took_VBD aspirin_NN for_IN
          six_CD months_NNS to_TO ten_CD years_NNS or_CC more_JJR than_IN ten_CD years_NNS ._. We_PRP also_RB
          evaluated_VBD a_DT combined_VBN measure_NN of_IN dosage_NN and_CC duration_NN by_IN
          computing_VBG tablet_NN years_NNS (_( tablets_NNS per_IN day_NN Ã—_NN years_NNS of_IN use_NN )_) ._.
          Reason_NNP for_IN analgesic_JJ use_NN was_VBD unavailable_JJ for_IN these_DT
          analyses_NNS ._.
        
        
          Statistical_NNP analyses_NNS
          Descriptive_NNP analyses_NNS included_VBD Student_NNP t-tests_JJ of_IN means_NNS
          for_IN cases_NNS and_CC controls_NNS for_IN continuous_JJ variables_NNS ,_, and_CC chi_NN
          square_JJ tests_NNS for_IN categorical_JJ variables_NNS ._. Unconditional_NNP
          logistic_JJ regression_NN was_VBD used_VBN to_TO calculate_VB odds_NNS ratios_NNS
          (_( ORs_NNP )_) and_CC 95_CD %_NN confidence_NN intervals_NNS (_( CIs_NNP )_) ._. ORs_NNP were_VBD
          adjusted_VBN for_IN potential_JJ confounders_NNS ,_, including_VBG age_NN ,_,
          education_NN ,_, and_CC packyears_NNS of_IN cigarettes_NNS smoked_VBD ._. Covariates_NNP
          were_VBD only_RB included_VBN in_IN the_DT final_JJ regression_NN model_NN if_IN they_PRP
          were_VBD established_VBN risk_NN factors_NNS in_IN these_DT data_NNS or_CC changed_VBD
          the_DT observed_VBN risk_NN estimates_NNS by_IN at_IN least_JJS 15_CD percent_NN ._.
          Variables_NNP that_WDT were_VBD evaluated_VBN but_CC not_RB included_VBN in_IN the_DT
          multivariate_NN model_NN were_VBD occupational_NN asbestos_NN exposure_NN ,_,
          dietary_JJ fruit_NN and_CC vegetable_NN intake_NN ,_, and_CC family_NN history_NN of_IN
          lung_NN cancer_NN ._. Participants_NNS classified_VBN as_IN non-users_JJ (_( i_NNP ._. e_SYM ._. ,_,
          those_DT who_WP did_VBD not_RB report_VB to_TO have_VB used_VBN aspirin_NN at_IN least_JJS
          once_RB a_DT week_NN for_IN at_IN least_JJS one_CD year_NN )_) served_VBD as_IN the_DT referent_NN
          category_NN throughout_IN the_DT logistic_JJ regression_NN analyses_NNS ._.
        
      
      
        Results_NNS
        Descriptive_NNP characteristics_NNS of_IN the_DT study_NN population_NN are_VBP
        shown_VBN in_IN Table_NNP 2_CD ._. Due_JJ to_TO the_DT matching_VBG procedures_NNS ,_, there_EX
        were_VBD no_DT differences_NNS between_IN cases_NNS and_CC controls_NNS with_IN respect_NN
        to_TO age_NN and_CC sex_NN ._. Cases_NNS were_VBD significantly_RB less_RBR likely_JJ than_IN
        controls_NNS to_TO have_VB obtained_VBN a_DT college_NN education_NN (_( p_NN <_NN
        0_CD ._. 001_CD )_) ._. As_IN expected_VBN ,_, cases_NNS were_VBD more_RBR likely_JJ than_IN controls_NNS
        to_TO be_VB former_JJ and_CC current_JJ smokers_NNS (_( p_NN <_NN 0_CD ._. 001_CD )_) ,_, and_CC to_TO
        have_VB had_VBN more_JJR packyears_NNS of_IN cigarettes_NNS (_( p_NN <_NN 0_CD ._. 001_CD )_) ._.
        Table_NNP 3_CD displays_NNS the_DT association_NN between_IN aspirin_NN use_NN and_CC
        lung_NN cancer_NN risk_NN in_IN the_DT total_JJ sample_NN ,_, as_RB well_RB as_IN among_IN
        females_NNS and_CC males_NNS separately_RB ._. Compared_VBN to_TO nonusers_NNS ,_, regular_JJ
        aspirin_NN use_NN was_VBD associated_VBN with_IN a_DT significant_JJ reduction_NN in_IN
        risk_NN of_IN lung_NN cancer_NN in_IN the_DT total_JJ study_NN sample_NN (_( adjusted_VBN OR_NNP
        =_SYM 0_CD ._. 57_CD ;_: 95_CD %_NN CI_NNP 0_CD ._. 41_CD -_: 0_CD ._. 78_CD )_) ,_, as_RB well_RB as_IN among_IN female_JJ
        (_( adjusted_VBN OR_NNP =_SYM 0_CD ._. 52_CD ;_: 95_CD %_NN CI_NNP 0_CD ._. 29_CD -_: 0_CD ._. 95_CD )_) and_CC male_JJ (_( adjusted_VBN
        OR_NNP =_SYM 0_CD ._. 62_CD ;_: 95_CD %_NN CI_NNP 0_CD ._. 43_CD -_: 0_CD ._. 90_CD )_) participants_NNS ._. Higher_JJR dosage_NN of_IN
        aspirin_NN (_( seven_CD or_CC more_JJR tablets_NNS per_IN week_NN )_) was_VBD significantly_RB
        associated_VBN with_IN risk_NN in_IN the_DT total_JJ sample_NN (_( adjusted_VBN OR_NNP =_SYM
        0_CD ._. 58_CD ;_: 95_CD %_NN CI_NNP 0_CD ._. 41_CD -_: 0_CD ._. 82_CD )_) and_CC among_IN male_JJ participants_NNS
        (_( adjusted_VBN OR_NNP =_SYM 0_CD ._. 56_CD ;_: 95_CD %_NN CI_NNP 0_CD ._. 37_CD -_: 0_CD ._. 83_CD )_) ._. Prolonged_NNP duration_NN
        of_IN use_NN (_( 11_CD or_CC more_JJR years_NNS )_) was_VBD not_RB associated_VBN with_IN a_DT
        significant_JJ reduction_NN in_IN risk_NN in_IN either_DT the_DT total_JJ sample_NN ,_,
        nor_CC among_IN the_DT subgroups_NNS defined_VBN by_IN sex_NN ._. However_RB ,_,
        self-reported_JJ aspirin_NN use_NN of_IN one_CD to_TO 10_CD years_NNS was_VBD associated_VBN
        with_IN a_DT significantly_RB lower_JJR risk_NN of_IN lung_NN cancer_NN in_IN all_DT
        groups_NNS ._. Among_IN male_JJ participants_NNS ,_, there_EX was_VBD evidence_NN of_IN a_DT
        dose_NN response_NN relationship_NN with_IN lower_JJR risk_NN as_IN a_DT function_NN of_IN
        longer_JJR duration_NN of_IN use_NN (_( p_NN <_NN 0_CD ._. 01_CD )_) ._. Risk_NN of_IN lung_NN cancer_NN
        was_VBD significantly_RB reduced_VBN in_IN relation_NN to_TO increasing_VBG tablet_NN
        years_NNS in_IN the_DT total_JJ sample_NN (_( p_NN <_NN 0_CD ._. 001_CD )_) and_CC in_IN males_NNS (_( p_NN
        <_NN 0_CD ._. 01_CD )_) ._. We_PRP further_JJ explored_JJ these_DT associations_NNS by_IN
        restricting_VBG the_DT sample_NN to_TO current_JJ and_CC former_JJ smokers_NNS ,_, who_WP
        were_VBD divided_VBN into_IN tertiles_NNS of_IN packyears_NNS of_IN cigarettes_NNS
        smoked_VBD ._. As_IN can_MD be_VB seen_VBN in_IN Table_NNP 4_CD ,_, risk_NN estimates_NNS for_IN the_DT
        exposure_NN categories_NNS described_VBD above_IN were_VBD generally_RB below_IN
        the_DT null_NN among_IN all_DT smoking_NN groups_NNS ._. However_RB ,_, statistically_RB
        significant_JJ risk_NN reductions_NNS and_CC dose-response_JJ relationships_NNS
        were_VBD only_RB observed_VBN for_IN participants_NNS in_IN the_DT lower_JJR tertile_NN of_IN
        packyear_NN distribution_NN (_( 1_CD -_: 34_CD packyears_NNS )_) ._. Table_NNP 5_CD displays_NNS the_DT
        association_NN between_IN regular_JJ aspirin_NN use_NN and_CC risk_NN of_IN
        histology-specific_JJ lung_NN cancer_NN ._. Significant_JJ risk_NN reductions_NNS
        were_VBD observed_VBN for_IN both_DT NSCLC_NNP (_( adjusted_VBN OR_NNP =_SYM 0_CD ._. 62_CD ;_: 95_CD %_NN CI_NNP
        0_CD ._. 45_CD -_: 0_CD ._. 86_CD )_) and_CC small_JJ cell_NN lung_NN cancer_NN (_( SCLC_NNP )_) (_( adjusted_VBN OR_NNP =_SYM
        0_CD ._. 32_CD ;_: 95_CD %_NN CI_NNP 0_CD ._. 16_CD -_: 0_CD ._. 63_CD )_) ._.
      
      
        Conclusions_NNP
        Results_NNS from_IN this_DT hospital-based_JJ case_NN control_NN study_NN are_VBP
        largely_RB consistent_JJ with_IN the_DT existing_VBG body_NN of_IN evidence_NN on_IN
        the_DT association_NN between_IN regular_JJ aspirin_NN use_NN and_CC lung_NN cancer_NN
        risk_NN ._. All_DT previous_JJ studies_NNS reported_VBD some_DT evidence_NN of_IN
        reduced_VBN risk_NN of_IN lung_NN cancer_NN in_IN relation_NN to_TO use_VB aspirin_NN or_CC
        other_JJ NSAIDs_NNP [_NN 14_CD 17_CD 18_CD 19_CD 20_CD 21_CD 22_CD 23_CD ]_NN ._. We_PRP observed_VBD a_DT
        significant_JJ risk_NN reduction_NN among_IN participants_NNS defined_VBN as_IN
        regular_JJ users_NNS in_IN the_DT total_JJ sample_NN ,_, as_RB well_RB as_IN among_IN men_NNS and_CC
        women_NNS separately_RB ._. Our_PRP$ data_NNS also_RB demonstrated_VBN significant_JJ
        risk_NN reductions_NNS associated_VBN with_IN higher_JJR aspirin_NN doses_NNS ,_,
        prolonged_JJ duration_NN ,_, and_CC greater_JJR tablet_NN years_NNS of_IN aspirin_NN
        use_NN ,_, although_IN significant_JJ trends_NNS were_VBD largely_RB restricted_VBN to_TO
        male_JJ participants_NNS ._. We_PRP further_RBR observed_VBD that_IN ,_, after_IN
        restricting_VBG the_DT analyses_NNS to_TO current_JJ and_CC former_JJ smokers_NNS ,_, the_DT
        chemoprotective_JJ effect_NN of_IN aspirin_NN was_VBD most_RBS apparent_JJ among_IN
        individuals_NNS in_IN the_DT lower_JJR tertile_NN of_IN the_DT packyear_NN
        distribution_NN ._. Finally_RB ,_, when_WRB we_PRP explored_JJ this_DT risk_NN
        association_NN among_IN histological_JJ subtypes_NNS ,_, significant_JJ risk_NN
        reductions_NNS were_VBD apparent_JJ in_IN when_WRB controls_NNS were_VBD compared_VBN to_TO
        patients_NNS with_IN both_DT NSCLC_NNP and_CC SCLC_NNP ._.
        Although_IN our_PRP$ findings_NNS follow_VBP the_DT general_JJ trend_NN that_WDT has_VBZ
        been_VBN demonstrated_VBN in_IN previous_JJ investigations_NNS ,_, some_DT
        differences_NNS exist_VBP ._. Two_CD cohort_NN studies_NNS reported_VBD reduced_VBN risk_NN
        among_IN aspirin_NN users_NNS among_IN females_NNS ,_, but_CC not_RB males_NNS [_NN 18_CD 19_CD ]_NN
        ,_, while_IN we_PRP observed_VBD strongest_JJS associations_NNS for_IN male_JJ
        participants_NNS ._. Another_DT study_NN did_VBD not_RB demonstrate_VB a_DT risk_NN
        reduction_NN among_IN females_NNS [_NN 20_CD ]_NN ,_, whereas_IN we_PRP consistently_RB
        found_VBD non-significant_JJ risk_NN estimates_NNS below_IN unity_NN for_IN female_JJ
        participants_NNS ._. In_IN a_DT recent_JJ report_NN based_VBN on_IN the_DT NYU_NNP Women_NNP 's_POS
        Health_NNP Study_NNP ,_, Akhmedkhanov_NNP et_CC al_NN ._. [_NN 22_CD ]_NN reported_VBD a_DT
        significant_JJ risk_NN reduction_NN for_IN NSCLC_NNP and_CC a_DT more_RBR modest_JJ ,_,
        non-significant_JJ decease_NN in_IN risk_NN for_IN all_DT histological_JJ types_NNS
        of_IN lung_NN cancer_NN ._. Our_PRP$ data_NNS are_VBP partly_RB in_IN contrast_NN to_TO these_DT
        results_NNS ,_, in_IN that_IN we_PRP observed_VBD the_DT most_JJS marked_VBN reduction_NN for_IN
        SCLC_NNP ,_, but_CC also_RB a_DT significant_JJ decrease_NN in_IN risk_NN for_IN all_DT NSCLC_NNP
        subtypes_NNS combined_VBN ._.
        These_DT discrepancies_NNS in_IN results_NNS may_MD be_VB partly_RB explained_VBN
        by_IN differences_NNS in_IN study_NN designs_NNS across_IN studies_NNS (_( i_NNP ._. e_SYM ._. ,_,
        randomized_JJ trial_NN [_NN 17_CD ]_NN ,_, cohort_NN study_NN [_NN 14_CD 18_CD 19_CD 22_CD ]_NN
        case-control_JJ study_NN [_NN 20_CD 23_CD ]_NN ,_, or_CC by_IN the_DT vast_JJ differences_NNS
        in_IN exposure_NN assessment_NN ,_, ranging_VBG from_IN assignment_NN of_IN
        participants_NNS to_TO aspirin_NN intervention_NN group_NN vs_NNS ._. placebo_NN
        group_NN [_NN 17_CD ]_NN over_IN ever_RB use_NN of_IN aspirin_NN in_IN the_DT last_JJ 30_CD days_NNS [_NN
        14_CD ]_NN to_TO having_VBG had_VBN an_DT NSAID_NNP prescription_NN in_IN the_DT past_JJ three_CD
        years_NNS [_NN 21_CD ]_NN ._.
        One_CD of_IN the_DT proposed_VBN mechanisms_NNS for_IN the_DT chemopreventive_JJ
        properties_NNS of_IN aspirin_NN and_CC other_JJ NSAIDs_NNP points_NNS to_TO the_DT
        observation_NN that_IN NSAIDs_NNP inhibit_VB prostaglandin_NN
        (_( PG_NNP )_) -_: endoperoxide_NN synthase_NN (_( cyclooxygenase_NN )_) enzymes_NNS [_NN 24_CD ]_NN
        ,_, of_IN which_WDT two_CD forms_NNS of_IN similar_JJ enzymatic_JJ activity_NN exist_VB ,_,
        COX-_NNP 1_CD and_CC COX-_NNP 2_CD ._. COX-_NNP 1_CD is_VBZ constitutively_RB expressed_VBN and_CC
        involved_VBN in_IN homeostasis_NNS [_NN 24_CD ]_NN ;_: COX-_NNP 2_CD is_VBZ induced_VBN and_CC
        involved_VBN in_IN inflammation_NN [_NN 24_CD 25_CD ]_NN ._. There_EX is_VBZ evidence_NN from_IN
        laboratory_NN studies_NNS to_TO suggest_VB that_IN the_DT COX-_NNP 2_CD pathway_NN may_MD be_VB
        involved_VBN in_IN lung_NN tumorigenesis_NNS ._. Bauer_NNP et_CC al_NN ._. [_NN 26_CD ]_NN
        reported_VBD significantly_RB higher_JJR levels_NNS of_IN COX-_NNP 2_CD enzymes_NNS in_IN
        mouse_NN lung_NN tumor_NN tissue_NN compared_VBN to_TO normal_JJ tissue_NN ._. It_PRP has_VBZ
        also_RB been_VBN shown_VBN that_DT aspirin_NN inhibited_VBD nitrosamine_NN induced_VBD
        lung_NN carcinogenesis_NNS [_NN 27_CD ]_NN ,_, and_CC it_PRP reduced_VBD COX-_NNP 2_CD enzyme_NN
        levels_NNS in_IN lung_NN cancer_NN cell_NN lines_NNS [_NN 28_CD ]_NN ._. Further_RB support_NN
        for_IN a_DT potential_JJ role_NN of_IN the_DT COX-_NNP 2_CD pathway_NN in_IN lung_NN cancer_NN
        development_NN comes_VBZ from_IN several_JJ investigations_NNS that_WDT
        demonstrated_VBD COX-_NNP 2_CD overexpression_NN in_IN human_JJ lung_NN tumors_NNS ,_,
        specifically_RB NSCLC_NNP [_NN 29_CD 30_CD 31_CD 32_CD ]_NN and_CC precursor_NN lesions_NNS [_NN
        33_CD ]_NN ._. While_IN COX-_NNP 2_CD expression_NN was_VBD generally_RB shown_VBN to_TO be_VB
        increased_VBN in_IN NSCLC_NNP and_CC to_TO a_DT much_RB lesser_JJR extent_NN in_IN SCLC_NNP ,_, the_DT
        role_NN of_IN COX-_NNP 2_CD expression_NN in_IN latter_JJ tumor_NN type_NN is_VBZ difficult_JJ
        to_TO determine_VB ,_, due_JJ to_TO the_DT fact_NN that_IN the_DT numbers_NNS of_IN SCLC_NNP
        tumors_NNS examined_VBD in_IN these_DT studies_NNS was_VBD very_RB small_JJ ._.
        Several_JJ methodological_JJ issues_NNS should_MD be_VB considered_VBN in_IN
        interpreting_VBG these_DT results_NNS ._. As_IN in_IN all_DT case-control_JJ studies_NNS ,_,
        bias_NN could_MD have_VB affected_VBN the_DT validity_NN of_IN the_DT current_JJ
        findings_NNS ._. Selection_NN bias_NN is_VBZ likely_JJ to_TO have_VB occurred_VBN in_IN this_DT
        investigation_NN ._. The_DT lung_NN cancer_NN patient_NN group_NN was_VBD restricted_VBN
        to_TO individuals_NNS who_WP were_VBD treated_VBN at_IN RPCI_NNP ,_, a_DT large_JJ regional_JJ
        cancer_NN treatment_NN center_NN ,_, and_CC are_VBP not_RB likely_JJ to_TO represent_VB
        the_DT general_JJ population_NN of_IN lung_NN cancer_NN patients_NNS in_IN the_DT
        western_JJ New_NNP York_NNP region_NN ._. However_RB ,_, it_PRP is_VBZ unlikely_JJ that_IN
        self-reported_JJ aspirin_NN use_NN would_MD be_VB different_JJ for_IN RPCI_NNP
        patients_NNS than_IN from_IN patients_NNS treated_VBN in_IN different_JJ
        facilities_NNS ._. The_DT use_NN of_IN hospital_NN controls_NNS might_MD introduce_VB
        bias_NN ,_, due_JJ to_TO the_DT possibility_NN that_IN some_DT controls_NNS were_VBD
        suffering_VBG from_IN conditions_NNS that_WDT would_MD make_VB them_PRP more_RBR likely_JJ
        to_TO use_VB aspirin_NN ._. However_RB ,_, greater_JJR likelihood_NN of_IN aspirin_NN use_NN
        in_IN the_DT control_NN group_NN would_MD only_RB have_VB attenuated_JJ the_DT true_JJ
        risk_NN estimate_NN ,_, rather_RB than_IN produced_VBN spurious_JJ associations_NNS ._.
        In_IN addition_NN ,_, hospital_NN controls_NNS were_VBD selected_VBN from_IN a_DT large_JJ
        pool_NN of_IN eligible_JJ participants_NNS with_IN a_DT wide_JJ variety_NN of_IN
        non-cancer_JJ diagnostic_JJ groups_NNS ,_, minimizing_VBG bias_NN arising_VBG from_IN
        potential_JJ overrepresentation_NN of_IN patients_NNS with_IN
        characteristics_NNS that_WDT may_MD be_VB associated_VBN with_IN the_DT exposures_NNS ._.
        In_IN fact_NN ,_, no_DT significant_JJ differences_NNS with_IN respect_NN to_TO aspirin_NN
        use_NN were_VBD observed_VBN for_IN the_DT most_RBS common_JJ diagnostic_JJ categories_NNS
        among_IN controls_NNS ._. Selection_NN bias_NN may_MD have_VB also_RB been_VBN
        introduced_VBN due_JJ to_TO the_DT low_JJ participation_NN rate_NN in_IN this_DT study_NN ._.
        Only_RB about_IN 50_CD percent_NN of_IN eligible_JJ cases_NNS and_CC controls_NNS agreed_VBD
        to_TO complete_VB the_DT PEDS_NNP questionnaire_NN ._. We_PRP have_VBP no_DT way_NN of_IN
        ascertaining_VBG whether_IN or_CC not_RB those_DT individuals_NNS who_WP refused_VBD
        to_TO complete_VB the_DT instrument_NN differed_VBD from_IN participants_NNS with_IN
        respect_NN to_TO aspirin_NN use_NN ._. Nevertheless_RB ,_, previous_JJ studies_NNS that_IN
        utilized_JJ the_DT PEDS_NNP data_NN base_VBP and_CC faced_VBD the_DT same_JJ
        methodological_JJ issue_NN ,_, consistently_RB replicated_VBN established_VBN
        epidemiological_JJ associations_NNS for_IN a_DT variety_NN of_IN cancer_NN sites_NNS ,_,
        including_VBG ovary_JJ [_NN 34_CD 35_CD ]_NN ,_, colon_NN [_NN 36_CD ]_NN ,_, breast_NN [_NN 37_CD ]_NN ,_,
        prostate_NN [_NN 38_CD ]_NN ,_, and_CC lung_NN [_NN 39_CD ]_NN ._. Recall_VB bias_NN is_VBZ always_RB a_DT
        problem_NN in_IN case-control_JJ studies_NNS of_IN cancer_NN ._. However_RB ,_, in_IN this_DT
        investigation_NN it_PRP may_MD have_VB been_VBN less_JJR of_IN an_DT issue_NN ,_, due_JJ to_TO our_PRP$
        use_NN of_IN hospital_NN controls_NNS ._. Further_RB ,_, the_DT questionnaire_NN used_VBN
        in_IN this_DT investigation_NN places_NNS no_DT particular_JJ emphasis_NN on_IN any_DT
        specific_JJ item_NN ._. Thus_RB ,_, there_EX is_VBZ little_JJ reason_NN to_TO believe_VB that_IN
        cases_NNS were_VBD more_RBR motivated_JJ than_IN controls_NNS to_TO recall_VB aspirin_NN
        use_NN ._. Exposure_NNP misclassification_NN may_MD also_RB have_VB affected_VBN our_PRP$
        results_NNS ,_, as_IN we_PRP based_VBD our_PRP$ analyses_NNS on_IN self-reported_JJ
        analgesic_JJ use_NN and_CC were_VBD not_RB able_JJ to_TO independently_RB verify_VB
        this_DT information_NN ._. Also_RB ,_, the_DT questionnaire_NN did_VBD not_RB assess_VB
        the_DT specific_JJ doses_NNS of_IN analgesic_JJ preparations_NNS ,_, such_JJ as_IN
        regular_JJ or_CC extra-strength_JJ tablets_NNS ._. Further_RB ,_, we_PRP did_VBD not_RB have_VB
        detailed_JJ information_NN on_IN other_JJ NSAIDs_NNP that_IN participants_NNS may_MD
        have_VB taken_VBN and_CC cannot_NN rule_NN out_RP the_DT possibility_NN that_IN cases_NNS
        may_MD have_VB been_VBN more_RBR likely_JJ to_TO have_VB taken_VBN preparations_NNS such_JJ
        as_IN ibuprofen_NN or_CC prescription_NN NSAIDs_NNP ,_, which_WDT would_MD have_VB
        resulted_VBN in_IN an_DT overestimated_JJ or_CC entirely_RB spurious_JJ results_NNS ._.
        However_RB ,_, we_PRP have_VBP no_DT reason_NN to_TO believe_VB that_IN any_DT of_IN these_DT
        potential_JJ sources_NNS of_IN misclassification_NN were_VBD differential_NN in_IN
        nature_NN ._.
        In_IN summary_NN ,_, in_IN this_DT hospital-based_JJ case-control_JJ study_NN of_IN
        lung_NN cancer_NN ,_, we_PRP observed_VBD consistent_JJ associations_NNS between_IN
        aspirin_NN use_NN and_CC risk_NN ,_, particularly_RB among_IN men_NNS ._. Although_IN a_DT
        number_NN of_IN epidemiological_JJ studies_NNS have_VBP produced_VBN fairly_RB
        consistent_JJ results_NNS ,_, none_NN of_IN these_DT investigations_NNS has_VBZ been_VBN
        specifically_RB designed_VBN to_TO address_VB this_DT research_NN question_NN ._.
        These_DT suggestive_JJ findings_NNS need_VBP to_TO be_VB replicated_VBN by_IN a_DT
        well-designed_JJ pharmacoepidemiological_JJ study_NN that_WDT
        incorporates_VBZ the_DT newly_RB introduced_VBN NSAID_NNP preparations_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        AR_NNP and_CC HS_NNP participated_VBD in_IN the_DT statistical_JJ analysis_NN and_CC
        drafting_VBG the_DT manuscript_NN ._. RJM_NNP participated_VBD in_IN study_NN design_NN ,_,
        statistical_JJ analysis_NN and_CC manuscript_NN preparation_NN ._. MER_NNP ,_, KMC_NNP ,_,
        KLF_NNP ,_, and_CC GML_NNP participated_VBD in_IN study_NN design_NN and_CC manuscript_NN
        preparation_NN ._. KBM_NNP and_CC GB_NNP conceived_VBD of_IN the_DT study_NN and_CC
        participated_VBD in_IN its_PRP$ design_NN and_CC manuscript_NN preparation_NN ._.
      
    
  
